Current status of next-generation vaccines against mpox virus: a scoping review DOI Creative Commons
Luis Alberto Bravo-Vázquez,

Daniela Bernal-Vázquez,

Asim K. Duttaroy

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 28, 2025

The mpox disease, caused by the virus (MPXV), has become a rising public health issue due to its potential cause outbreaks. Consistently, this investigation aims evaluate current advances in development of novel immunotherapeutic approaches against MPXV, which are crucial for preventing and controlling spread. This scoping review was performed analyzing content English-language articles published between 2018 2024, reported next-generation vaccines MPXV their assessment animal models. Patents within scope research were also included. Contrarywise, studies based solely on immunoinformatic methods, reviews, book chapters, news, others excluded. literature search executed 11 databases, such as Scopus, MEDLINE, PubMed. A total 36 records (32 4 patents) included review. All 32 contain preclinical with varied group sizes (4-16) main models BALB/c mice. Less commonly used CAST/Ei mice cynomolgus macaques. Moreover, most targeted one or more antigens, A29L, A35R, B6R, M1R, through active immunization (via mRNAs recombinant antigens) passive (antibody delivery). Overall, new generation might represent prospective candidates combat concern. Nonetheless, several analyzed possess drawbacks, including limited similarity humans, small sizes, brief follow-up durations. Consequently, additional is required ascertain long-term protection, efficacy, safety these approaches.

Язык: Английский

Current status of next-generation vaccines against mpox virus: a scoping review DOI Creative Commons
Luis Alberto Bravo-Vázquez,

Daniela Bernal-Vázquez,

Asim K. Duttaroy

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 28, 2025

The mpox disease, caused by the virus (MPXV), has become a rising public health issue due to its potential cause outbreaks. Consistently, this investigation aims evaluate current advances in development of novel immunotherapeutic approaches against MPXV, which are crucial for preventing and controlling spread. This scoping review was performed analyzing content English-language articles published between 2018 2024, reported next-generation vaccines MPXV their assessment animal models. Patents within scope research were also included. Contrarywise, studies based solely on immunoinformatic methods, reviews, book chapters, news, others excluded. literature search executed 11 databases, such as Scopus, MEDLINE, PubMed. A total 36 records (32 4 patents) included review. All 32 contain preclinical with varied group sizes (4-16) main models BALB/c mice. Less commonly used CAST/Ei mice cynomolgus macaques. Moreover, most targeted one or more antigens, A29L, A35R, B6R, M1R, through active immunization (via mRNAs recombinant antigens) passive (antibody delivery). Overall, new generation might represent prospective candidates combat concern. Nonetheless, several analyzed possess drawbacks, including limited similarity humans, small sizes, brief follow-up durations. Consequently, additional is required ascertain long-term protection, efficacy, safety these approaches.

Язык: Английский

Процитировано

0